Sarilumab: patient-reported outcomes in rheumatoid arthritis

Sarilumab: patient-reported outcomes in rheumatoid arthritis

Chiara Crotti,1,2 Martina Biggioggero,3 Andrea Becciolini,3 Ennio Giulio Favalli3 1Department of Clinical Sciences and Health Community, University of Milan, 2Division of Rheumatology, Gaetano Pini Institute, Milan, Italy; 3Department of Rheumatology, Gaetano Pini Institute, Milan, Italy Abstract: I...

Full description

Bibliographic Details
Main Authors:	Crotti C, Biggioggero M, Becciolini A, Favalli EG
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-08-01
Series:	Patient Related Outcome Measures
Subjects:	rheumatoid arthritis interleukin-6 sarilumab patient reported outcome
Online Access:	https://www.dovepress.com/sarilumab-patient-reported-outcomes-in-rheumatoid-arthritis-peer-reviewed-article-PROM

Similar Items

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
by: Raimondo MG, et al.
Published: (2017-05-01)

New possibilities of drug therapy for rheumatoid arthritis: focus at sarilumab
by: D. E. Karateev, et al.
Published: (2019-11-01)

Inhibitor of biological effects of interleukin-6 sarilumab in treatment of rheumatoid arthritis
by: D. E. Karateev, et al.
Published: (2019-12-01)

The efficacy and safety of sarilumab, fully human monoclonal antibodies against interleukin 6 receptor, in rheumatoid arthritis: new evidence
by: E. L. Nasonov, et al.
Published: (2019-11-01)

Efficacy and safety of sarilumab in combination with methotrexate in patients with active rheumatoid arthritis and inadequate effect of methotrexate monotherapy (results of phase III MOBILITY study)
by: E. L. Nasonov, et al.
Published: (2019-05-01)

Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab
by: Andrea Rubbert-Roth, et al.
Published: (2022-08-01)

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
by: Vibeke Strand, et al.
Published: (2018-06-01)

Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies
by: Mark C. Genovese, et al.
Published: (2020-06-01)

High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab
by: Vibeke Strand, et al.
Published: (2020-10-01)

Sarilumab use in severe Coronavirus Disease 2019 pneumonia
by: Ahmed M.A. El Fattah Amer, et al.
Published: (2023-01-01)

Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis
by: Luis Sainz, et al.
Published: (2023-11-01)

Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
by: Yoshiya Tanaka, et al.
Published: (2019-03-01)

Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection
by: Biggioggero M, et al.
Published: (2018-12-01)

Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date
by: Crotti C, et al.
Published: (2017-01-01)

Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
by: V. T. Ivashkin, et al.
Published: (2023-12-01)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
by: Martina Biggioggero, et al.
Published: (2019-10-01)

Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison
by: Thomas Huizinga, et al.
Published: (2023-02-01)

Patient and clinician perspectives on a patient‐facing dashboard that visualizes patient reported outcomes in rheumatoid arthritis
by: Lucy H. Liu, et al.
Published: (2020-08-01)

Tolerability of Sarilumab – An anti-interleukin-6 receptor monoclonal antibody is controversial for the management of COVID-19
by: Justin Jacob Abraham, et al.
Published: (2021-01-01)

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis
by: Wolfgang A. Schmidt, et al.
Published: (2023-10-01)

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
by: Cem Gabay, et al.
Published: (2020-04-01)

Impact of tofacitinib on patient outcomes in rheumatoid arthritis – review of clinical studies
by: Boyce EG, et al.
Published: (2016-01-01)

Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts
by: Annett Klinder, et al.
Published: (2022-06-01)

Patient’s perspective of sustained remission in rheumatoid arthritis
by: Irazú Contreras-Yáñez, et al.
Published: (2017-09-01)

The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry
by: Favalli EG, et al.
Published: (2018-05-01)

Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations
by: Andrea Marino, et al.
Published: (2022-05-01)

Polymyalgia Rheumatica Treated with Sarilumab
by: Anvitha Madhavaram, et al.
Published: (2023-12-01)

Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date
by: Lazzerini PE, et al.
Published: (2016-09-01)

Comparison of Psoriatic Arthritis and Rheumatoid Arthritis Patients across Body Mass Index Categories in Switzerland
by: Enriqueta Vallejo-Yagüe, et al.
Published: (2021-07-01)

Case of successful use of sarilumab in secondary renal amyloidosis in a patient with rheumatoid arthritis
by: L. A. Smirnova, et al.
Published: (2022-11-01)

The perspective of Polish patients with rheumatoid arthritis – treatment expectations, patient-reported outcomes, and digital literacy (the SENSE study)
by: Marcin Stajszczyk, et al.
Published: (2023-10-01)

Datasets of YY1 expression in rheumatoid arthritis patients
by: Jinpiao Lin, et al.
Published: (2016-12-01)

Which patient reported outcome domains are important to the rheumatologists while assessing patients with rheumatoid arthritis?
by: Aprajita Jagpal, et al.
Published: (2019-09-01)

The effect of olokizumab on rheumatoid arthritis patient’s reported outcomes: results of a double-blind randomized placebo-controlled multicenter phase III trial (CREDO 1)
by: E. L. Nasonov, et al.
Published: (2021-03-01)

Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
by: Mark Genovese, et al.
Published: (2018-03-01)

Association between ultrasound images and patient-reported outcomes in the treatment of rheumatoid arthritis: a retrospective study
by: Masao Nawata, et al.
Published: (2021-11-01)

Primary pathologic role of interleukin-6 in rheumatoid arthritis
by: G.L. Bajocchi, et al.
Published: (2013-05-01)

PROMIS Fatigue short forms are reliable and valid in adults with rheumatoid arthritis
by: Clifton O. Bingham III, et al.
Published: (2019-02-01)

Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis
by: Zhan-Guo Li, et al.
Published: (2018-01-01)

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
by: Alvin F. Wells, et al.
Published: (2019-05-01)